In the future, the detailed mechanistic understanding of PON2’s effects on ASGR1, coupled with the in vivo evidence of its therapeutic potential, may open up new possibilities for the development of targeted therapies for metabolic diseases, particularly hypercholesterolemia. This evidence concerns the gene ASGR1 and Hypercholesterolemia.